5 Best 52-Week High US Stocks to Buy

4. Dianthus Therapeutics Inc (NASDAQ:DNTH)

Stock Price as of April 21: $91.42

52-Week Range: $16.64 – $96.50

Stock Upside Potential: 34.20%

Number of Hedge Fund Holders: 52

Dianthus Therapeutics Inc (NASDAQ:DNTH) is among the best 52-week high US stocks to buy. On March 26, William Blair reaffirmed an Outperform rating on Dianthus Therapeutics Inc (NASDAQ:DNTH) stock. This action followed an FDA update on safety requirements for Dianthus Therapeutics’ claseprubart clinical trials.

In the safety update, the FDA has dropped antinuclear antibodies as screening criteria. Also, the regulator has removed the requirement for routine ANA testing during claseprubart clinical trials. These changes make it easier for Dianthus Therapeutics to enroll patients and run the trials.

Notably, Dianthus can now enroll patients into the claseprubart studies without screening and removing participants for ANAs. According to William Blair, the FDA decision may have a positive impact on the potential drug’s labeling.

The firm noted that the CAPTIVATE trial interim responder analysis met its best-case scenario. As a result, William Blair believes claseprubart has a differentiated product profile.

Claseprubart is being developed as a potential therapy for various autoimmune disorders in areas with unmet needs. Dianthus Therapeutics plans to initiate a Phase 3 trial of claseprubart in patients with gMG in mid-2026. It expects topline results from this study in the second half of 2028.

A Phase 2 trial of claseprubart in patients with MMN is ongoing and topline results are expected in the second half of 2026. Also, the company targets to provide topline results from the CAPTIVATE trial Part B by the end of 2026.

Dianthus Therapeutics Inc (NASDAQ:DNTH) is an American biotech company focused on developing best-in-class antibody therapeutics. Its work is focused on therapies for patients living with severe autoimmune diseases to address unmet medical needs.